Zeenat Safdar, MD

Associate Professor of Medicine, Academic Institute
Associate Clinical Member, Research Institute
Houston Methodist
Weill Cornell Medical College


Biography

Dr. Zeenat Safdar is an Associate Professor of Medicine, Houston Methodist Academic Institute, and Director of Clinical Research and Pulmonary Hypertension Program, Houston Methodist Hospital Lung Center in Houston, Texas. She is also an Adjunct Associate Professor of Medicine at Baylor College of Medicine.

Dr. Safdar serves as a Chair of Young Council at Pulmonary Vascular Research Institute, Pulmonology Chair at the Pulmonary Hypertension Association Online University, and National Chair at PHA on the Road program. She serves as Registries and Databases Workforce leader at PH council of International Society of Heart Lung Transplantation (ISHLT).

Dr. Safdar is a Fellow of the American College of Physicians, American College of Chest Physicians (CHEST), and Pulmonary Vascular Research Institute. She is a member of the PH Council of International Society of Heart Lung Transplant, American Thoracic Society and Texas Medical Association.

She has been invited to serve as the session facilitator, presenter, and abstract reviewer and selector at the International Conference of the ATS, CHEST and ISHLT. Dr. Safdar has served as an invited reviewer for the American Journal of Respiratory and Critical Care Medicine, Respiratory Medicine and Therapeutic Advances in Respiratory Disease and serves as a member of the editorial board of several journals.

Description of Research

Dr. Safdar’s principal area of interest is Pulmonary Arterial Hypertension (PAH), specifically translational research, clinical research and clinical trials. Her recent research has focused on the contribution of renin-angiotensin-aldosterone system to the pathophysiology of PAH. She is the principal and co-investigator of several ongoing clinical trials including

  • REATA - a phase 2 dose-ranging study of efficacy and safety of Bardoxolone Methyl in PAH
  • LIBERTY - a phase 2 study of Ubenimex in patient with PAH
  • TRANSIT-1 - a study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in PAH
  • Chronic ThromboEmbolic Pulmonary Hypertension registry
  • TRITON - The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed PAH
  • RIN-PH - Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

 The Houston Methodist Hospital Pulmonary Hypertension program also provides expert care for patients with idiopathic pulmonary fibrosis (IPF). As a Director of the IPF program, she serves as a lead investigator of several ongoing IPF clinical trials including 

  • RIFF study - a phase 2 randomized placebo-controlled clinical study to assess the safety and efficacy of Lebrikizumab in IPF
  • RAINIER study - a phase 2 multicenter study to assess the efficacy and safety of Simtuzamab in IPF

 She was the site investigator of several complete IPF clinical trials such as

  • ARTEMIS-IPF - ambrisentan for IPF
  • ARTEMIS-PH - ambrisentan in PH associated with IPF
  • MUSIC - macitentan for IPF

 Dr. Safdar is the recipient of a K23 grant from the National Institute of Health (NIH) and several other grants from non-profit organizations.  Her research has been published in prominent, high impact journals.

Areas Of Expertise

Pulmonary Arterial Hypertension (PAH) Idiopathic Pulmonary Fibrosis (IPF) Pulmonary disease
Publications

Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: A Delphi consensus study
Rahaghi, FF, Safdar, Z, Brown, AW, De Andrade, JA, Flaherty, KR, Kaner, RJ, King, CS, Padilla, ML, Noth, I, Scholand, MB, Shifren, A & Nathan, SD 2020, , BMC Pulmonary Medicine, vol. 20, no. 1, 191. https://doi.org/10.1186/s12890-020-01209-4

Associations between patient-reported outcomes and death or lung transplant in idiopathic pulmonary fibrosis data from the idiopathic pulmonary fibrosis prospective outcomes registry
IPF-PRO Registry investigators 2020, , Annals of the American Thoracic Society, vol. 17, no. 6, pp. 699-705. https://doi.org/10.1513/AnnalsATS.201906-437OC

Spironolactone in pulmonary arterial hypertension: results of a cross-over study
Safdar, Z, Frost, AE, Basant, A, Deswal, A, O’Brian Smith, E & Entman, M 2020, , Pulmonary Circulation, vol. 10, no. 2. https://doi.org/10.1177/2045894019898030

Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial
Preston, IR, Burger, CD, Bartolome, S, Safdar, Z, Krowka, M, Sood, N, Ford, HJ, Battarjee, WF, Chakinala, MM, Gomberg-Maitland, M & Hill, NS 2020, , Journal of Heart and Lung Transplantation, vol. 39, no. 5, pp. 464-472. https://doi.org/10.1016/j.healun.2019.12.008

Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry
IPF-PRO Registry investigators 2020, , CHEST, vol. 157, no. 5, pp. 1188-1198. https://doi.org/10.1016/j.chest.2019.11.042

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
Wells, AU, Flaherty, KR, Brown, KK, Inoue, Y, Devaraj, A, Richeldi, L, Moua, T, Crestani, B, Wuyts, WA, Stowasser, S, Quaresma, M, Goeldner, RG, Schlenker-Herceg, R, Kolb, M, Abe, S, Aburto, M, Acosta, O, Andrews, C, Antin-Ozerkis, D, Arce, G, Arias, M, Avdeev, S, Barczyk, A, Bascom, R, Bazdyrev, E, Beirne, P, Belloli, E, Bergna, MA, Bergot, E, Bhatt, N, Blaas, S, Bondue, B, Bonella, F, Britt, E, Buch, K, Burk, J, Cai, H, Cantin, A, Castillo Villegas, DM, Cazaux, A, Cerri, S, Chaaban, S, Chaudhuri, N, Cottin, V, Crestani, B, Criner, G, Dahlqvist, C, Danoff, S, Dematte DAmico, J, Dilling, D, Elias, P, Ettinger, N, Falk, J, Fernández Pérez, ER, Gamez-Dubuis, A, Giessel, G, Gifford, A, Glassberg, M, Glazer, C, Golden, J, Gómez Carrera, L, Guiot, J, Hallowell, R, Hayashi, H, Hetzel, J, Hirani, N, Homik, L, Hope-Gill, B, Hotchkin, D, Ichikado, K, Ilkovich, M, Inoue, Y, Izumi, S, Jassem, E, Jones, L, Jouneau, S, Kaner, R, Kang, J, Kawamura, T, Kessler, R, Kim, Y, Kishi, K, Kitamura, H, Kolb, M, Kondoh, Y, Kono, C, Koschel, D, Kreuter, M, Kulkarni, T, Kus, J, Lebargy, F, León Jiménez, A, Luo, Q, Mageto, Y, Maher, TM, Makino, S, Marchand-Adam, S, Marquette, C, Martinez, R, Martínez, M, Maturana Rozas, R, Miyazaki, Y, Moiseev, S, Molina-Molina, M, Morrison, L, Morrow, L, Moua, T, Nambiar, A, Nishioka, Y, Nunes, H, Okamoto, M, Oldham, J, Otaola, M, Padilla, M, Park, JS, Patel, N, Pesci, A, Piotrowski, W, Pitts, L, Poonyagariyagorn, H, Prasse, A, Quadrelli, S, Randerath, W, Refini, R, Reynaud-Gaubert, M, Riviere, F, Rodríguez Portal, JA, Rosas, I, Rossman, M, Safdar, Z, Saito, T, Sakamoto, N, Salinas Fénero, M, Sauleda, J, Schmidt, S, Scholand, MB, Schwartz, M, Shapera, S, Shlobin, O, Sigal, B, Silva Orellana, A, Skowasch, D, Song, JW, Stieglitz, S, Stone, H, Strek, M, Suda, T, Sugiura, H, Takahashi, H, Takaya, H, Takeuchi, T, Thavarajah, K, Tolle, L, Tomassetti, S, Tomii, K, Valenzuela, C, Vancheri, C, Varone, F, Veeraraghavan, S, Villar, A, Weigt, S, Wemeau, L, Wuyts, W, Xu, Z, Yakusevich, V, Yamada, Y, Yamauchi, H & Ziora, D 2020, , The Lancet Respiratory Medicine, vol. 8, no. 5, pp. 453-460. https://doi.org/10.1016/S2213-2600(20)30036-9

Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort
Todd, JL, Vinisko, R, Liu, Y, Neely, ML, Overton, R, Flaherty, KR, Noth, I, Newby, LK, Lasky, JA, Olman, MA, Hesslinger, C, Leonard, TB, Palmer, SM, Belperio, JA, Asi, W, Baker, A, Beegle, S, Condos, R, Cordova, F, Culver, DA, Luckhardt, T, Dilling, D, Glassberg, M, Gulati, M, Guntupalli, K, Gupta, N, Hotchkin, D, Huie, T, Kaner, R, Kim, H, Kreider, M, Lancaster, L, Lederer, D, Lee, D, Liesching, T, Lipchik, R, Lobo, J, Mageto, Y, Menon, P, Morrison, L, Namen, A, Oldham, J, Raj, R, Ramaswamy, M, Russell, T, Sachs, P, Safdar, Z, Sigal, B, Silhan, L, Strek, M, Suliman, S, Tabak, J, Walia, R & Whelan, TP 2020, , BMC Pulmonary Medicine, vol. 20, no. 1, 64. https://doi.org/10.1186/s12890-020-1103-4

Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension
Oriaku, I, Patel, A & Safdar, Z 2020, , Pulmonary Circulation, vol. 10, no. 1. https://doi.org/10.1177/2045894019898032

Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry
Todd, JL, Neely, ML, Overton, R, Durham, K, Gulati, M, Huang, H, Roman, J, Newby, LK, Flaherty, KR, Vinisko, R, Liu, Y, Roy, J, Schmid, R, Strobel, B, Hesslinger, C, Leonard, TB, Noth, I, Belperio, JA, Palmer, SM, Asi, W, Baker, A, Beegle, S, Belperio, JA, Condos, R, Cordova, F, Culver, DA, De Andrade, JAM, Dilling, D, Flaherty, KR, Glassberg, M, Gulati, M, Guntupalli, K, Gupta, N, Case, AH, Hotchkin, D, Huie, T, Kaner, R, Kim, H, Kreider, M, Lancaster, L, Lasky, J, Lederer, D, Lee, D, Liesching, T, Lipchik, R, Lobo, J, Mageto, Y, Menon, P, Morrison, L, Namen, A, Oldham, J, Raj, R, Ramaswamy, M, Russell, T, Sachs, P, Safdar, Z, Sigal, B, Silhan, L, Strek, M, Suliman, S, Tabak, J, Walia, R & Whelan, TP 2019, , Respiratory Research, vol. 20, no. 1, 227. https://doi.org/10.1186/s12931-019-1190-z

Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: Insights from the IPF-PRO Registry
Snyder, L, Neely, ML, Hellkamp, AS, OBrien, E, De Andrade, J, Conoscenti, CS, Leonard, T, Bender, S, Gulati, M, Culver, DA, Kaner, RJ, Palmer, S, Kim, HJ, Asi, W, Baker, A, Beegle, S, Belperio, JA, Condos, R, Cordova, F, De Andrade, JAM, Dilling, D, Flaherty, K, Glassberg, M, Guntupalli, K, Gupta, N, Case, AH, Hotchkin, D, Huie, T, Kreider, M, Lancaster, L, Lasky, J, Lederer, D, Lee, D, Liesching, T, Lipchik, R, Lobo, J, Mageto, Y, Menon, P, Morrison, L, Namen, A, Oldham, J, Raj, R, Ramaswamy, M, Russell, T, Sachs, P, Safdar, Z, Sigal, B, Silhan, L, Strek, M, Suliman, S, Tabak, J, Walia, R, Whelan, TP, Fleming, J & Morris, W 2019, Respiratory Research, vol. 20, no. 1, 105. https://doi.org/10.1186/s12931-019-1043-9

Risk stratification and medical therapy of pulmonary arterial hypertension
Galiè, N, Channick, RN, Frantz, RP, Grünig, E, Jing, ZC, Moiseeva, O, Preston, IR, Pulido, T, Safdar, Z, Tamura, Y & McLaughlin, VV 2019, , The European respiratory journal, vol. 53, no. 1. https://doi.org/10.1183/13993003.01889-2018

Longitudinal change in pulmonary arterial capacitance as an indicator of prognosis and response to therapy and in pulmonary arterial hypertension
Medrek, SK, Kloefkorn, C, Nguyen, DTM, Graviss, EA, Frost, AE & Safdar, Z 2017, , Pulmonary Circulation, vol. 7, no. 2, pp. 399-408. https://doi.org/10.1177/2045893217698715

Tolerability of Switch to Macitentan from Bosentan in Pulmonary Arterial Hypertension
Safdar, Z, Thakur, A & Frost, AE 2017, , Southern Medical Journal, vol. 110, no. 3, pp. 223-228. https://doi.org/10.14423/SMJ.0000000000000607

Efficacy of 1, 5, and 20mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: A randomized, double-blind study with open-label extension
Vizza, CD, Sastry, BKS, Safdar, Z, Harnisch, L, Gao, X, Zhang, M, Lamba, M & Jing, ZC 2017, , BMC Pulmonary Medicine, vol. 17, no. 1, 44. https://doi.org/10.1186/s12890-017-0374-x

Longitudinal change in pulmonary arterial capacitance as an indicator of prognosis and response to therapy and in pulmonary arterial hypertension
Medrek, SK, Kloefkorn, C, Nguyen, DTM, Graviss, EA, Frost, AE & Safdar, Z 2017, Pulmonary Circulation, vol 7, no. 2, pp. 399-408. DOI: 10.1177/2045893217698715

Recommendations for the use of oral treprostinil in clinical practice: A delphi consensus project pulmonary circulation
Rahaghi, FF, Feldman, JP, Allen, RP, Tapson, V, Safdar, Z, Balasubramanian, VP, Shapiro, S, Mathier, MA, Elwing, JM, Chakinala, MM & White, RJ 2017, , Pulmonary Circulation, vol. 7, no. 1, pp. 167-174. https://doi.org/10.1086/690109

Pulmonary hypertension
Pandit, LM & Safdar, Z 2017, . in Cardiology Secrets. Elsevier, pp. 597-606. https://doi.org/10.1016/B978-0-323-47870-0.00069-6

Epidemiology and Pathophysiology of Chronic Thromboembolic Pulmonary Hypertension: Risk Factors and Mechanisms
Medrek, S & Safdar, Z 2016, Methodist DeBakey cardiovascular journal, vol. 12, no. 4, pp. 195-198. https://doi.org/10.14797/mdcj-12-4-195

Statement on pregnancy in pulmonary hypertension from the pulmonary vascular research institute
Hemnes, AR, Kiely, DG, Cockrill, BA, Safdar, Z, Wilson, VJ, Hazmi, MA, Preston, IR, Maclean, MR & Lahm, T 2015, , Pulmonary Circulation, vol. 5, no. 3, pp. 435-465. https://doi.org/10.1086/682230

Critical role for IL-18 in spontaneous lung inflammation caused by autophagy deficiency
Fattah, EA, Bhattacharya, A, Herron, A, Safdar, Z & Eissa, NT 2015, , Journal of Immunology, vol. 194, no. 11, pp. 5407-5416. https://doi.org/10.4049/jimmunol.1402277